Linagliptin for elderly patients with type 2 diabetes - Authors' reply

Affiliations

¹ Diabetes Centre, Heart of England NHS Foundation Trust, and University of Birmingham, Birmingham, B9 5SS, UK. Electronic address: anthony.barnett@heartofengland.nhs.uk.
² Boehringer Ingelheim, Ingelheim, Germany.
³ Boehringer Ingelheim, Bracknell, UK.

Comment

Anthony H Barnett et al. Lancet. 2014.

. 2014 Jan 25;383(9914):307-8.

doi: 10.1016/S0140-6736(14)60104-5.

¹ Diabetes Centre, Heart of England NHS Foundation Trust, and University of Birmingham, Birmingham, B9 5SS, UK. Electronic address: anthony.barnett@heartofengland.nhs.uk.
² Boehringer Ingelheim, Ingelheim, Germany.
³ Boehringer Ingelheim, Bracknell, UK.

No abstract available

Comment on

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ. Barnett AH, et al. Lancet. 2013 Oct 26;382(9902):1413-23. doi: 10.1016/S0140-6736(13)61500-7. Epub 2013 Aug 13. Lancet. 2013. PMID: 23948125 Clinical Trial.
Linagliptin for elderly patients with type 2 diabetes.
Yamada T. Yamada T. Lancet. 2014 Jan 25;383(9914):306. doi: 10.1016/S0140-6736(14)60101-X. Lancet. 2014. PMID: 24461120 No abstract available.
Linagliptin for elderly patients with type 2 diabetes.
Shah R. Shah R. Lancet. 2014 Jan 25;383(9914):306-7. doi: 10.1016/S0140-6736(14)60102-1. Lancet. 2014. PMID: 24461121 No abstract available.
Linagliptin for elderly patients with type 2 diabetes.
Salvo F, Moore N, Pariente A. Salvo F, et al. Lancet. 2014 Jan 25;383(9914):307. doi: 10.1016/S0140-6736(14)60103-3. Lancet. 2014. PMID: 24461122 No abstract available.